Synthetic organic

AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

InformationAZD3759 is a potent, oral active, CNS-penetrantEGFRinhibitor withIC50of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.TargetsEGFR (L858R) (Cell-free assay): EGFR (exon 19Del)

InformationAZD3759 is a potent, oral active, CNS-penetrantEGFRinhibitor withIC50of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.TargetsEGFR (L858R) (Cell-free assay): EGFR (exon 19Del)

InformationAZD3759 is a potent, oral active, CNS-penetrantEGFRinhibitor withIC50of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.TargetsEGFR (L858R) (Cell-free assay): EGFR (exon 19Del)

InformationAZD3759 is a potent, oral active, CNS-penetrantEGFRinhibitor withIC50of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.TargetsEGFR (L858R) (Cell-free assay): EGFR (exon 19Del)

InformationAZD3759 is a potent, oral active, CNS-penetrantEGFRinhibitor withIC50of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.TargetsEGFR (L858R) (Cell-free assay): EGFR (exon 19Del)

AZD3778.

AZD3778.

Shipped at 4°C. Store at -20°C.

Shipped at 4°C. Store at -20°C.

Shipped at 4°C. Store at -20°C.